Medabon Kit (WHO / SRA quality combi-pack)

Medabon Kit is a quality-assured medical abortion combi-pack containing mifepristone 200 mg and misoprostol 4 x 200 mcg tablets for the non-surgical termination of early pregnancy up to 63 days since the last menstrual period. The product meets Stringent Regulatory Authority (SRA) quality standards and is widely included in reproductive health programs.

Key Features:

• Quality: SRA-approved combi-pack manufactured by Sun Pharmaceutical Industries.

• Contents: One mifepristone 200 mg tablet plus four misoprostol 200 mcg tablets.

• Indication: Medical termination of intrauterine pregnancy up to 9 weeks gestation.

• Mechanism of Action:

  • Mifepristone blocks progesterone, disrupting the hormonal support of early pregnancy.

  • Misoprostol induces uterine contractions to complete the expulsion process.

• Administration: Following the mifepristone dose, misoprostol is administered per clinical protocol, typically within 24–48 hours.

• Safety & Follow-Up: Use requires clinical assessment; follow-up care is recommended to confirm completion and manage side effects.

Clinical Benefits:

• Non-surgical option with documented global use.

• Recognized in multiple countries’ reproductive health protocols.

• Supported by quality assurance frameworks, including SRA approval.

Common Considerations:
Medabon should only be used under appropriate medical supervision, with adherence to local regulatory requirements and clinical guidelines. Side effects can include uterine cramps, bleeding, nausea, and gastrointestinal symptoms. Follow-up care is essential to assess treatment success and safety.